Share Price and Basic Stock Data
Last Updated: October 20, 2025, 9:20 pm
| PEG Ratio | -8.99 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Glenmark Life Sciences Ltd operates in the pharmaceuticals sector, with a current price of ₹1,881 and a market capitalization of ₹53,072 Cr. The company reported a trailing twelve-month (TTM) sales figure of ₹13,342 Cr, which reflects a growth trend from ₹12,990 Cr in FY 2023. The quarterly sales have shown variability; for instance, sales for Mar 2024 stood at ₹3,063 Cr, while Jun 2024 reported ₹3,244 Cr. However, a notable decline occurred in Dec 2023, with sales dropping to ₹2,507 Cr, indicating potential seasonal or market-related fluctuations. This variability may raise concerns among investors regarding the consistency of revenue generation. Overall, Glenmark’s sales performance remains competitive in the pharmaceutical industry, but further analysis is needed to understand the underlying factors affecting these fluctuations.
Profitability and Efficiency Metrics
Glenmark Life Sciences’ profitability has experienced significant fluctuations, with operating profit margins (OPM) recorded at 18% for FY 2025, up from 10% in FY 2024. The net profit for FY 2025 reached ₹1,047 Cr, a recovery from a net loss of ₹1,434 Cr in FY 2024. The earnings per share (EPS) also rebounded to ₹37.11 from a negative ₹53.22 the previous year. The return on equity (ROE) was reported at 15.8%, while the return on capital employed (ROCE) improved to 19.4%. However, the interest coverage ratio (ICR) stood at 11.90x, indicating strong capability to meet interest obligations. Despite these positive metrics, the company has faced challenges, particularly in the Dec 2023 quarter, where it recorded an operating loss of ₹209 Cr. This inconsistency highlights the need for improved operational efficiency and stable revenue streams.
Balance Sheet Strength and Financial Ratios
The balance sheet of Glenmark Life Sciences demonstrates a solid financial foundation with total assets of ₹15,991 Cr and total liabilities of ₹14,358 Cr as of Mar 2025, resulting in a manageable debt-to-equity ratio of 0.24. The company has reserves amounting to ₹8,821 Cr against borrowings of ₹2,473 Cr, indicating a healthy reserve position relative to its debt. The liquidity ratios also reflect stability, with a current ratio of 1.56 and a quick ratio of 1.05, suggesting sufficient short-term assets to cover liabilities. However, the cash conversion cycle (CCC) of 129 days indicates that the company takes longer to convert investments in inventory and accounts receivable into cash. This could potentially strain cash flows, necessitating a review of inventory management and collection processes to enhance operational efficiency.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Glenmark Life Sciences shows a diverse ownership structure, with promoters holding 46.64% of the shares, while foreign institutional investors (FIIs) and domestic institutional investors (DIIs) hold 20.62% and 17.64%, respectively. The public holds 15.05% of the shares, reflecting a healthy mix of institutional and retail interest. The number of shareholders has decreased from 3,13,540 in Sep 2022 to 1,90,210 by Jun 2025, which may indicate a consolidation trend or loss of confidence among smaller investors. The consistent promoter stake suggests long-term commitment, while the fluctuation in institutional holdings, particularly FIIs, which decreased from 23.14% in Sep 2022 to 20.62% in Jun 2025, could raise concerns about investor sentiment and market perception.
Outlook, Risks, and Final Insight
If margins sustain their recovery and operational efficiencies improve, Glenmark Life Sciences could enhance its profitability and market position. However, risks remain, including potential fluctuations in sales, as evidenced by the significant drop in Dec 2023 sales figures, and the extended cash conversion cycle that may affect liquidity. Additionally, the company must navigate competitive pressures within the pharmaceutical sector, which could impact pricing and market share. If the management addresses these operational challenges effectively, there is potential for growth and improved investor confidence, leading to a stronger financial performance in the coming years. The overall health of the company’s balance sheet provides a solid foundation for future endeavors, but vigilance in operational management will be crucial for sustaining growth and profitability.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Glenmark Life Sciences Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 151 Cr. | 120 | 247/84.3 | 34.5 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.96 Cr. | 2.07 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,927 Cr. | 453 | 458/192 | 110 | 22.8 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.9 Cr. | 47.1 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 30.0 Cr. | 20.5 | 29.1/17.0 | 31.3 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,937.33 Cr | 1,190.62 | 50.38 | 194.07 | 0.33% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,777 | 3,018 | 3,100 | 3,001 | 3,036 | 3,207 | 2,507 | 3,063 | 3,244 | 3,434 | 3,388 | 3,256 | 3,264 |
| Expenses | 2,346 | 2,539 | 2,626 | 2,603 | 2,599 | 2,745 | 2,715 | 2,559 | 2,656 | 2,832 | 2,787 | 2,695 | 2,684 |
| Operating Profit | 432 | 479 | 474 | 398 | 437 | 462 | -209 | 504 | 588 | 602 | 600 | 561 | 581 |
| OPM % | 16% | 16% | 15% | 13% | 14% | 14% | -8% | 16% | 18% | 18% | 18% | 17% | 18% |
| Other Income | 183 | 86 | 209 | -696 | -32 | -205 | 87 | 351 | 31 | 39 | 31 | -361 | -297 |
| Interest | 60 | 83 | 97 | 109 | 112 | 121 | 134 | 149 | 40 | 48 | 52 | 67 | 58 |
| Depreciation | 147 | 146 | 152 | 135 | 142 | 141 | 147 | 151 | 118 | 120 | 123 | 125 | 130 |
| Profit before tax | 408 | 337 | 435 | -542 | 151 | -6 | -403 | 555 | 462 | 473 | 456 | 8 | 96 |
| Tax % | 48% | 17% | 33% | -26% | -14% | 997% | -18% | 319% | 26% | 25% | 24% | 45% | 51% |
| Net Profit | 211 | 279 | 291 | -403 | 173 | -62 | -331 | -1,214 | 340 | 354 | 348 | 4 | 47 |
| EPS in Rs | 6.82 | 9.23 | 9.66 | -15.18 | 5.31 | -2.90 | -12.45 | -43.17 | 12.06 | 12.55 | 12.33 | 0.16 | 1.66 |
Last Updated: August 19, 2025, 2:37 pm
Below is a detailed analysis of the quarterly data for Glenmark Life Sciences Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 3,264.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,256.00 Cr. (Mar 2025) to 3,264.00 Cr., marking an increase of 8.00 Cr..
- For Expenses, as of Jun 2025, the value is 2,684.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2,695.00 Cr. (Mar 2025) to 2,684.00 Cr., marking a decrease of 11.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 581.00 Cr.. The value appears strong and on an upward trend. It has increased from 561.00 Cr. (Mar 2025) to 581.00 Cr., marking an increase of 20.00 Cr..
- For OPM %, as of Jun 2025, the value is 18.00%. The value appears strong and on an upward trend. It has increased from 17.00% (Mar 2025) to 18.00%, marking an increase of 1.00%.
- For Other Income, as of Jun 2025, the value is -297.00 Cr.. The value appears strong and on an upward trend. It has increased from -361.00 Cr. (Mar 2025) to -297.00 Cr., marking an increase of 64.00 Cr..
- For Interest, as of Jun 2025, the value is 58.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 67.00 Cr. (Mar 2025) to 58.00 Cr., marking a decrease of 9.00 Cr..
- For Depreciation, as of Jun 2025, the value is 130.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 125.00 Cr. (Mar 2025) to 130.00 Cr., marking an increase of 5.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 96.00 Cr.. The value appears strong and on an upward trend. It has increased from 8.00 Cr. (Mar 2025) to 96.00 Cr., marking an increase of 88.00 Cr..
- For Tax %, as of Jun 2025, the value is 51.00%. The value appears to be increasing, which may not be favorable. It has increased from 45.00% (Mar 2025) to 51.00%, marking an increase of 6.00%.
- For Net Profit, as of Jun 2025, the value is 47.00 Cr.. The value appears strong and on an upward trend. It has increased from 4.00 Cr. (Mar 2025) to 47.00 Cr., marking an increase of 43.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.66. The value appears strong and on an upward trend. It has increased from 0.16 (Mar 2025) to 1.66, marking an increase of 1.50.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:15 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6,005 | 6,563 | 7,562 | 9,079 | 9,074 | 9,865 | 10,641 | 10,944 | 12,305 | 12,990 | 11,813 | 13,322 | 13,342 |
| Expenses | 4,914 | 5,348 | 6,125 | 7,043 | 7,457 | 8,280 | 8,942 | 8,860 | 9,978 | 10,712 | 10,618 | 10,970 | 10,998 |
| Operating Profit | 1,091 | 1,214 | 1,437 | 2,037 | 1,617 | 1,586 | 1,699 | 2,084 | 2,327 | 2,278 | 1,195 | 2,351 | 2,344 |
| OPM % | 18% | 18% | 19% | 22% | 18% | 16% | 16% | 19% | 19% | 18% | 10% | 18% | 18% |
| Other Income | 11 | -180 | 20 | -44 | 89 | 375 | 191 | 95 | -101 | -449 | 336 | -259 | -587 |
| Interest | 189 | 190 | 179 | 237 | 286 | 335 | 377 | 353 | 298 | 350 | 516 | 207 | 226 |
| Depreciation | 217 | 300 | 234 | 264 | 302 | 326 | 417 | 444 | 487 | 611 | 582 | 486 | 498 |
| Profit before tax | 697 | 544 | 1,044 | 1,491 | 1,119 | 1,301 | 1,096 | 1,382 | 1,441 | 868 | 434 | 1,399 | 1,032 |
| Tax % | 22% | 61% | 29% | 26% | 28% | 29% | 29% | 30% | 31% | 57% | 430% | 25% | |
| Net Profit | 546 | 209 | 743 | 1,109 | 804 | 925 | 776 | 970 | 994 | 377 | -1,434 | 1,047 | 754 |
| EPS in Rs | 19.99 | 7.72 | 26.33 | 39.29 | 28.49 | 32.78 | 27.50 | 34.38 | 33.37 | 10.53 | -53.22 | 37.11 | 26.70 |
| Dividend Payout % | 0% | 26% | 8% | 5% | 7% | 6% | 9% | 7% | 7% | 24% | -5% | 7% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -61.72% | 255.50% | 49.26% | -27.50% | 15.05% | -16.11% | 25.00% | 2.47% | -62.07% | -480.37% | 173.01% |
| Change in YoY Net Profit Growth (%) | 0.00% | 317.22% | -206.24% | -76.76% | 42.55% | -31.16% | 41.11% | -22.53% | -64.55% | -418.30% | 653.38% |
Glenmark Life Sciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 5% |
| 3 Years: | 3% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 12% |
| 3 Years: | 6% |
| TTM: | 159% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 33% |
| 3 Years: | 74% |
| 1 Year: | 16% |
| Return on Equity | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | -1% |
| 3 Years: | -10% |
| Last Year: | 16% |
Last Updated: September 5, 2025, 3:36 pm
Balance Sheet
Last Updated: September 10, 2025, 3:45 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 27 | 27 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 |
| Reserves | 2,956 | 1,756 | 3,601 | 4,464 | 5,135 | 5,577 | 6,042 | 7,036 | 9,058 | 9,446 | 7,820 | 8,821 |
| Borrowings | 3,267 | 3,800 | 3,988 | 4,724 | 4,639 | 4,449 | 4,869 | 4,986 | 3,962 | 4,608 | 1,231 | 2,473 |
| Other Liabilities | 2,176 | 2,726 | 2,575 | 2,548 | 2,793 | 3,235 | 3,729 | 3,524 | 4,003 | 5,289 | 5,279 | 4,669 |
| Total Liabilities | 8,427 | 8,309 | 10,193 | 11,764 | 12,595 | 13,289 | 14,668 | 15,575 | 17,052 | 19,371 | 14,358 | 15,991 |
| Fixed Assets | 3,091 | 2,015 | 2,594 | 2,755 | 3,030 | 3,670 | 5,029 | 5,129 | 5,887 | 5,422 | 4,210 | 4,487 |
| CWIP | 5 | 477 | 543 | 708 | 1,122 | 1,399 | 1,222 | 1,382 | 1,010 | 1,190 | 662 | 835 |
| Investments | 0 | 17 | 17 | 16 | 15 | 30 | 25 | 25 | 50 | 45 | 790 | 56 |
| Other Assets | 5,331 | 5,799 | 7,039 | 8,285 | 8,429 | 8,190 | 8,393 | 9,040 | 10,105 | 12,715 | 8,697 | 10,613 |
| Total Assets | 8,427 | 8,309 | 10,193 | 11,764 | 12,595 | 13,289 | 14,668 | 15,575 | 17,052 | 19,371 | 14,358 | 15,991 |
Below is a detailed analysis of the balance sheet data for Glenmark Life Sciences Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 28.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 28.00 Cr..
- For Reserves, as of Mar 2025, the value is 8,821.00 Cr.. The value appears strong and on an upward trend. It has increased from 7,820.00 Cr. (Mar 2024) to 8,821.00 Cr., marking an increase of 1,001.00 Cr..
- For Borrowings, as of Mar 2025, the value is 2,473.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 1,231.00 Cr. (Mar 2024) to 2,473.00 Cr., marking an increase of 1,242.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 4,669.00 Cr.. The value appears to be improving (decreasing). It has decreased from 5,279.00 Cr. (Mar 2024) to 4,669.00 Cr., marking a decrease of 610.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 15,991.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 14,358.00 Cr. (Mar 2024) to 15,991.00 Cr., marking an increase of 1,633.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 4,487.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,210.00 Cr. (Mar 2024) to 4,487.00 Cr., marking an increase of 277.00 Cr..
- For CWIP, as of Mar 2025, the value is 835.00 Cr.. The value appears strong and on an upward trend. It has increased from 662.00 Cr. (Mar 2024) to 835.00 Cr., marking an increase of 173.00 Cr..
- For Investments, as of Mar 2025, the value is 56.00 Cr.. The value appears to be declining and may need further review. It has decreased from 790.00 Cr. (Mar 2024) to 56.00 Cr., marking a decrease of 734.00 Cr..
- For Other Assets, as of Mar 2025, the value is 10,613.00 Cr.. The value appears strong and on an upward trend. It has increased from 8,697.00 Cr. (Mar 2024) to 10,613.00 Cr., marking an increase of 1,916.00 Cr..
- For Total Assets, as of Mar 2025, the value is 15,991.00 Cr.. The value appears strong and on an upward trend. It has increased from 14,358.00 Cr. (Mar 2024) to 15,991.00 Cr., marking an increase of 1,633.00 Cr..
Notably, the Reserves (8,821.00 Cr.) exceed the Borrowings (2,473.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -2.00 | -2.00 | -2.00 | -2.00 | -3.00 | -3.00 | -3.00 | -2.00 | -1.00 | -2.00 | 0.00 | 0.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 131 | 140 | 120 | 97 | 94 | 81 | 83 | 86 | 92 | 115 | 57 | 92 |
| Inventory Days | 191 | 247 | 249 | 299 | 244 | 244 | 211 | 230 | 208 | 203 | 208 | 254 |
| Days Payable | 279 | 379 | 308 | 243 | 225 | 241 | 210 | 226 | 190 | 172 | 210 | 216 |
| Cash Conversion Cycle | 43 | 8 | 61 | 152 | 113 | 85 | 84 | 90 | 110 | 147 | 56 | 129 |
| Working Capital Days | 62 | 47 | 51 | 125 | 99 | 64 | 54 | 67 | 65 | 141 | -2 | 44 |
| ROCE % | 15% | 16% | 19% | 21% | 15% | 15% | 14% | 15% | 16% | 10% | 12% | 19% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Mid-Cap Opportunities Fund - Regular Plan | 8,778,612 | 1.62 | 1212.5 | N/A | N/A | N/A |
| Mirae Asset Large & Midcap Fund | 3,313,007 | 1.21 | 457.59 | N/A | N/A | N/A |
| Mirae Asset ELSS Tax Saver Fund | 2,689,916 | 1.5 | 371.53 | 2,550,247 | 2025-06-29 09:52:48 | 5.48% |
| Invesco India Contra Fund | 1,662,235 | 1.27 | 229.59 | 1,510,869 | 2025-06-29 09:52:49 | 10.02% |
| Mirae Asset Midcap Fund | 1,472,836 | 1.32 | 203.43 | N/A | N/A | N/A |
| Invesco India Mid Cap Fund | 1,323,818 | 3.02 | 182.85 | 1,173,731 | 2025-06-29 09:52:49 | 12.79% |
| Invesco India Large & Mid Cap Fund | 1,205,107 | 2.46 | 166.45 | N/A | N/A | N/A |
| Kotak Equity Arbitrage Fund - Regular Plan | 1,127,100 | 0.25 | 155.68 | N/A | N/A | N/A |
| HDFC Manufacturing Fund | 1,100,000 | 1.3 | 151.93 | N/A | N/A | N/A |
| Invesco India Arbitrage Fund | 1,021,150 | 0.7 | 141.04 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 37.11 | -53.22 | 10.53 | 33.37 | 34.38 |
| Diluted EPS (Rs.) | 37.11 | -53.22 | 10.53 | 33.37 | 34.38 |
| Cash EPS (Rs.) | 54.33 | -30.18 | 35.04 | 52.46 | 50.10 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 313.60 | 278.09 | 348.70 | 334.48 | 250.36 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 313.60 | 278.09 | 348.70 | 334.48 | 250.36 |
| Revenue From Operations / Share (Rs.) | 472.08 | 418.62 | 460.36 | 436.08 | 387.85 |
| PBDIT / Share (Rs.) | 87.36 | 72.13 | 91.97 | 88.14 | 75.65 |
| PBIT / Share (Rs.) | 70.13 | 51.50 | 70.31 | 70.89 | 59.93 |
| PBT / Share (Rs.) | 49.58 | 1.29 | 30.78 | 51.08 | 48.99 |
| Net Profit / Share (Rs.) | 37.11 | -50.80 | 13.37 | 35.21 | 34.38 |
| NP After MI And SOA / Share (Rs.) | 37.11 | -53.21 | 10.53 | 33.37 | 34.38 |
| PBDIT Margin (%) | 18.50 | 17.22 | 19.97 | 20.21 | 19.50 |
| PBIT Margin (%) | 14.85 | 12.30 | 15.27 | 16.25 | 15.45 |
| PBT Margin (%) | 10.50 | 0.30 | 6.68 | 11.71 | 12.63 |
| Net Profit Margin (%) | 7.86 | -12.13 | 2.90 | 8.07 | 8.86 |
| NP After MI And SOA Margin (%) | 7.86 | -12.71 | 2.28 | 7.65 | 8.86 |
| Return on Networth / Equity (%) | 11.83 | -19.13 | 3.13 | 10.36 | 13.73 |
| Return on Capital Employeed (%) | 19.62 | 17.01 | 13.84 | 16.13 | 14.83 |
| Return On Assets (%) | 6.52 | -10.45 | 1.53 | 5.51 | 6.21 |
| Long Term Debt / Equity (X) | 0.05 | 0.00 | 0.40 | 0.28 | 0.55 |
| Total Debt / Equity (X) | 0.24 | 0.12 | 0.45 | 0.40 | 0.66 |
| Asset Turnover Ratio (%) | 0.87 | 0.70 | 0.71 | 0.42 | 0.42 |
| Current Ratio (X) | 1.56 | 1.28 | 1.96 | 1.77 | 1.75 |
| Quick Ratio (X) | 1.05 | 0.84 | 1.37 | 1.23 | 1.21 |
| Inventory Turnover Ratio (X) | 4.81 | 1.15 | 1.31 | 1.85 | 1.85 |
| Dividend Payout Ratio (NP) (%) | 6.73 | -4.69 | 23.73 | 7.49 | 7.27 |
| Dividend Payout Ratio (CP) (%) | 4.60 | -7.66 | 7.76 | 4.93 | 4.99 |
| Earning Retention Ratio (%) | 93.27 | 104.69 | 76.27 | 92.51 | 92.73 |
| Cash Earning Retention Ratio (%) | 95.40 | 107.66 | 92.24 | 95.07 | 95.01 |
| Interest Coverage Ratio (X) | 11.90 | 3.94 | 7.42 | 8.34 | 6.04 |
| Interest Coverage Ratio (Post Tax) (X) | 7.86 | -0.80 | 4.27 | 5.21 | 3.62 |
| Enterprise Value (Cr.) | 43947.27 | 26350.45 | 16364.27 | 15087.86 | 16656.12 |
| EV / Net Operating Revenue (X) | 3.30 | 2.23 | 1.26 | 1.23 | 1.52 |
| EV / EBITDA (X) | 17.83 | 12.95 | 6.31 | 6.07 | 7.80 |
| MarketCap / Net Operating Revenue (X) | 3.26 | 2.29 | 1.01 | 1.01 | 1.20 |
| Retention Ratios (%) | 93.26 | 104.69 | 76.26 | 92.50 | 92.72 |
| Price / BV (X) | 4.91 | 3.44 | 1.38 | 1.37 | 1.86 |
| Price / Net Operating Revenue (X) | 3.26 | 2.29 | 1.01 | 1.01 | 1.20 |
| EarningsYield | 0.02 | -0.05 | 0.02 | 0.07 | 0.07 |
After reviewing the key financial ratios for Glenmark Life Sciences Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 37.11. This value is within the healthy range. It has increased from -53.22 (Mar 24) to 37.11, marking an increase of 90.33.
- For Diluted EPS (Rs.), as of Mar 25, the value is 37.11. This value is within the healthy range. It has increased from -53.22 (Mar 24) to 37.11, marking an increase of 90.33.
- For Cash EPS (Rs.), as of Mar 25, the value is 54.33. This value is within the healthy range. It has increased from -30.18 (Mar 24) to 54.33, marking an increase of 84.51.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 313.60. It has increased from 278.09 (Mar 24) to 313.60, marking an increase of 35.51.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 313.60. It has increased from 278.09 (Mar 24) to 313.60, marking an increase of 35.51.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 472.08. It has increased from 418.62 (Mar 24) to 472.08, marking an increase of 53.46.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 87.36. This value is within the healthy range. It has increased from 72.13 (Mar 24) to 87.36, marking an increase of 15.23.
- For PBIT / Share (Rs.), as of Mar 25, the value is 70.13. This value is within the healthy range. It has increased from 51.50 (Mar 24) to 70.13, marking an increase of 18.63.
- For PBT / Share (Rs.), as of Mar 25, the value is 49.58. This value is within the healthy range. It has increased from 1.29 (Mar 24) to 49.58, marking an increase of 48.29.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 37.11. This value is within the healthy range. It has increased from -50.80 (Mar 24) to 37.11, marking an increase of 87.91.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 37.11. This value is within the healthy range. It has increased from -53.21 (Mar 24) to 37.11, marking an increase of 90.32.
- For PBDIT Margin (%), as of Mar 25, the value is 18.50. This value is within the healthy range. It has increased from 17.22 (Mar 24) to 18.50, marking an increase of 1.28.
- For PBIT Margin (%), as of Mar 25, the value is 14.85. This value is within the healthy range. It has increased from 12.30 (Mar 24) to 14.85, marking an increase of 2.55.
- For PBT Margin (%), as of Mar 25, the value is 10.50. This value is within the healthy range. It has increased from 0.30 (Mar 24) to 10.50, marking an increase of 10.20.
- For Net Profit Margin (%), as of Mar 25, the value is 7.86. This value is within the healthy range. It has increased from -12.13 (Mar 24) to 7.86, marking an increase of 19.99.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 7.86. This value is below the healthy minimum of 8. It has increased from -12.71 (Mar 24) to 7.86, marking an increase of 20.57.
- For Return on Networth / Equity (%), as of Mar 25, the value is 11.83. This value is below the healthy minimum of 15. It has increased from -19.13 (Mar 24) to 11.83, marking an increase of 30.96.
- For Return on Capital Employeed (%), as of Mar 25, the value is 19.62. This value is within the healthy range. It has increased from 17.01 (Mar 24) to 19.62, marking an increase of 2.61.
- For Return On Assets (%), as of Mar 25, the value is 6.52. This value is within the healthy range. It has increased from -10.45 (Mar 24) to 6.52, marking an increase of 16.97.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 24) to 0.05, marking an increase of 0.05.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.24. This value is within the healthy range. It has increased from 0.12 (Mar 24) to 0.24, marking an increase of 0.12.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.87. It has increased from 0.70 (Mar 24) to 0.87, marking an increase of 0.17.
- For Current Ratio (X), as of Mar 25, the value is 1.56. This value is within the healthy range. It has increased from 1.28 (Mar 24) to 1.56, marking an increase of 0.28.
- For Quick Ratio (X), as of Mar 25, the value is 1.05. This value is within the healthy range. It has increased from 0.84 (Mar 24) to 1.05, marking an increase of 0.21.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.81. This value is within the healthy range. It has increased from 1.15 (Mar 24) to 4.81, marking an increase of 3.66.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 6.73. This value is below the healthy minimum of 20. It has increased from -4.69 (Mar 24) to 6.73, marking an increase of 11.42.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 4.60. This value is below the healthy minimum of 20. It has increased from -7.66 (Mar 24) to 4.60, marking an increase of 12.26.
- For Earning Retention Ratio (%), as of Mar 25, the value is 93.27. This value exceeds the healthy maximum of 70. It has decreased from 104.69 (Mar 24) to 93.27, marking a decrease of 11.42.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 95.40. This value exceeds the healthy maximum of 70. It has decreased from 107.66 (Mar 24) to 95.40, marking a decrease of 12.26.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 11.90. This value is within the healthy range. It has increased from 3.94 (Mar 24) to 11.90, marking an increase of 7.96.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 7.86. This value is within the healthy range. It has increased from -0.80 (Mar 24) to 7.86, marking an increase of 8.66.
- For Enterprise Value (Cr.), as of Mar 25, the value is 43,947.27. It has increased from 26,350.45 (Mar 24) to 43,947.27, marking an increase of 17,596.82.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.30. This value exceeds the healthy maximum of 3. It has increased from 2.23 (Mar 24) to 3.30, marking an increase of 1.07.
- For EV / EBITDA (X), as of Mar 25, the value is 17.83. This value exceeds the healthy maximum of 15. It has increased from 12.95 (Mar 24) to 17.83, marking an increase of 4.88.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.26. This value exceeds the healthy maximum of 3. It has increased from 2.29 (Mar 24) to 3.26, marking an increase of 0.97.
- For Retention Ratios (%), as of Mar 25, the value is 93.26. This value exceeds the healthy maximum of 70. It has decreased from 104.69 (Mar 24) to 93.26, marking a decrease of 11.43.
- For Price / BV (X), as of Mar 25, the value is 4.91. This value exceeds the healthy maximum of 3. It has increased from 3.44 (Mar 24) to 4.91, marking an increase of 1.47.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.26. This value exceeds the healthy maximum of 3. It has increased from 2.29 (Mar 24) to 3.26, marking an increase of 0.97.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from -0.05 (Mar 24) to 0.02, marking an increase of 0.07.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Glenmark Life Sciences Ltd:
- Net Profit Margin: 7.86%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 19.62% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 11.83% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 7.86
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.05
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 39.2 (Industry average Stock P/E: 50.38)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.24
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 7.86%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | B/2, Mahalaxmi Chambers, Mumbai Maharashtra 400026 | complianceofficer@glenmarkpharma.com http://www.glenmarkpharma.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Glenn Saldanha | Chairman & Managing Director |
| Mrs. Cherylann Pinto | Executive Director |
| Mr. Anurag Mantri | Executive Director & Global CFO |
| Mrs. B E Saldanha | Non Executive Director |
| Ms. Saira Ramasastry | Ind. Non-Executive Director |
| Mrs. Vijayalakshmi Iyer | Ind. Non-Executive Director |
| Mr. Pradeep Kumar Sinha | Ind. Non-Executive Director |
| Mr. Dipankar Bhattacharjee | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Glenmark Life Sciences Ltd?
Glenmark Life Sciences Ltd's intrinsic value (as of 21 October 2025) is 1557.85 which is 15.93% lower the current market price of 1,853.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 52,304 Cr. market cap, FY2025-2026 high/low of 2,286/1,275, reserves of ₹8,821 Cr, and liabilities of 15,991 Cr.
What is the Market Cap of Glenmark Life Sciences Ltd?
The Market Cap of Glenmark Life Sciences Ltd is 52,304 Cr..
What is the current Stock Price of Glenmark Life Sciences Ltd as on 21 October 2025?
The current stock price of Glenmark Life Sciences Ltd as on 21 October 2025 is 1,853.
What is the High / Low of Glenmark Life Sciences Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Glenmark Life Sciences Ltd stocks is 2,286/1,275.
What is the Stock P/E of Glenmark Life Sciences Ltd?
The Stock P/E of Glenmark Life Sciences Ltd is 39.2.
What is the Book Value of Glenmark Life Sciences Ltd?
The Book Value of Glenmark Life Sciences Ltd is 314.
What is the Dividend Yield of Glenmark Life Sciences Ltd?
The Dividend Yield of Glenmark Life Sciences Ltd is 0.13 %.
What is the ROCE of Glenmark Life Sciences Ltd?
The ROCE of Glenmark Life Sciences Ltd is 19.4 %.
What is the ROE of Glenmark Life Sciences Ltd?
The ROE of Glenmark Life Sciences Ltd is 15.8 %.
What is the Face Value of Glenmark Life Sciences Ltd?
The Face Value of Glenmark Life Sciences Ltd is 1.00.